Pancreatic cancer remains one of the most difficult cancers to treat, particularly once it has spread to other parts of the body.
But a new investigational drug called daraxonrasib is generating significant interest after results from a large Phase III clinical trial showed substantially longer survival compared with standard chemotherapy in people with previously treated metastatic pancreatic cancer.
The results were published in the New England Journal of Medicine in May 2026 and presented at the 2026 American Society of Clinical Oncology Annual Meeting.
The findings are promising enough that the U.S. Food and Drug Administration has also allowed an expanded-access program that may provide the medication to certain eligible patients before formal FDA approval.
Here is what the research actually found and why oncologists are paying attention.
What Is Pancreatic Cancer?
The pancreas is an organ located behind the stomach that helps with digestion and blood sugar regulation.
Several types of cancer can develop in the pancreas, but the most common is pancreatic ductal adenocarcinoma, often abbreviated PDAC.
Unfortunately, pancreatic cancer can be difficult to detect early. Symptoms may not become obvious until the disease is more advanced.
Possible symptoms include:
- Unexplained weight loss
- Loss of appetite
- Abdominal or back pain
- Yellowing of the skin or eyes, known as jaundice
- Dark urine
- Light-colored stools
- Nausea
- Fatigue
- New or worsening diabetes
These symptoms can have many causes and do not necessarily indicate pancreatic cancer.
Why Is Pancreatic Cancer So Difficult to Treat?
One major challenge is that pancreatic cancer is frequently diagnosed after it has already grown beyond the pancreas or spread to other organs.
Surgery can potentially cure some pancreatic cancers when the tumor can be completely removed, but many patients are not candidates for surgery when they are diagnosed.
Chemotherapy therefore plays an important role in treating advanced disease.
Unfortunately, once metastatic pancreatic cancer progresses despite initial chemotherapy, treatment options become more limited.
Researchers have spent decades trying to identify better ways of attacking pancreatic cancer cells.
One of the most important targets is a group of proteins known as RAS.
What Is RAS?
RAS proteins help control signals telling cells when to grow and divide.
Normally, these signals can be switched on and off.
In many cancer cells, however, mutations cause the RAS signaling pathway to remain abnormally active. The result can be continuous signals encouraging cancer cells to grow and survive.
This is particularly important in pancreatic cancer.
More than 90% of pancreatic ductal adenocarcinomas have an oncogenic RAS mutation, making the pathway an extremely attractive treatment target.
The problem is that RAS was historically considered extraordinarily difficult to target with medication.
That is beginning to change.
What Is Daraxonrasib?
Daraxonrasib, previously known as RMC-6236, is an experimental oral cancer medication designed to inhibit active RAS signaling.
It belongs to a newer class of medications known as RAS(ON) inhibitors.
The “ON” refers to the active state of the RAS protein.
Rather than targeting only one specific RAS mutation, daraxonrasib is designed to inhibit multiple forms of active RAS.
That potentially matters in pancreatic cancer because different patients can have different RAS mutations.
Researchers wanted to determine whether blocking this pathway could translate into something much more important than simply shrinking tumors:
Could it actually help patients live longer?
What Did the Phase III Trial Find?
The RASolute 302 trial enrolled 500 people with previously treated metastatic pancreatic ductal adenocarcinoma.
Participants had already received one previous line of treatment for metastatic disease.
They were randomly assigned to receive either:
- Daraxonrasib, or
- Standard chemotherapy selected by the treating investigator
Of the 500 participants, 248 received daraxonrasib and 252 received chemotherapy.
Approximately 92% had tumors containing RAS G12 mutations.
The results were striking.
Overall Survival
Among the entire study population:
Daraxonrasib:
Median overall survival was 13.2 months.
Chemotherapy:
Median overall survival was 6.7 months.
In other words, median survival was almost twice as long among patients receiving daraxonrasib.
Researchers reported a hazard ratio for death of 0.40, representing a substantial reduction in the risk of death during the study period.
Progression-Free Survival
Researchers also measured how long patients lived before their cancer worsened.
Median progression-free survival was:
Daraxonrasib:
7.2 months
Chemotherapy:
3.6 months
Again, the difference strongly favored daraxonrasib.
What About Patients With RAS G12 Mutations?
Because RAS G12 mutations represented the large majority of cancers in the study, researchers specifically analyzed this population.
The results were very similar.
Median overall survival was:
13.2 months with daraxonrasib
compared with
6.6 months with chemotherapy.
Median progression-free survival was:
7.3 months with daraxonrasib
compared with
3.5 months with chemotherapy.
Both differences were statistically significant.
Does This Mean Daraxonrasib Cures Pancreatic Cancer?
No.
This distinction is extremely important.
Daraxonrasib did not cure metastatic pancreatic cancer in this study.
The cancer remained a serious and ultimately life-threatening disease for many participants.
What the trial demonstrated was that patients receiving daraxonrasib lived substantially longer, on average, than those receiving the chemotherapy treatments used for comparison.
For a disease in which effective treatment options after initial therapy are limited, that represents an important potential advance.
Did Daraxonrasib Have Side Effects?
Yes.
Daraxonrasib is a cancer medication, and significant side effects occurred.
In the Phase III trial, severe or medically significant adverse events classified as Grade 3 or higher occurred in approximately:
61.8% of patients receiving daraxonrasib
compared with
69.6% receiving chemotherapy.
One interesting difference involved stopping treatment because of side effects.
Treatment-related side effects caused approximately 1.2% of patients receiving daraxonrasib to discontinue treatment compared with 11.2% of patients receiving chemotherapy.
This does not mean daraxonrasib is free of significant side effects. Patients receiving the medication still require close oncology monitoring.
Is Daraxonrasib FDA Approved?
Not yet.
As of August 2026, daraxonrasib remains an investigational medication.
However, several FDA actions demonstrate the level of interest surrounding the treatment.
The FDA has granted daraxonrasib:
- Breakthrough Therapy designation
- Orphan Drug designation for pancreatic cancer
- A Commissioner’s National Priority Voucher
These programs can help accelerate the development and review of treatments addressing serious diseases and unmet medical needs.
But none of these designations is the same as FDA approval.
The FDA still must review the complete evidence regarding the medication’s effectiveness, safety, manufacturing and other requirements before deciding whether to approve it.
Can Patients Receive Daraxonrasib Before FDA Approval?
Some patients may be able to.
In May 2026, the FDA allowed Revolution Medicines to proceed with an expanded-access treatment protocol for daraxonrasib.
Expanded access is sometimes referred to as “compassionate use.”
It allows certain patients with serious or life-threatening illnesses to potentially receive an investigational medication outside a traditional clinical trial when appropriate criteria are met.
The daraxonrasib expanded-access program is intended for patients with previously treated metastatic pancreatic ductal adenocarcinoma.
Access is not automatic.
A physician licensed in the United States must request expanded access from the drug’s sponsor on behalf of an eligible patient, and additional requirements apply.
Patients interested in investigational treatment should discuss clinical trials and expanded-access possibilities with their oncology team.
Why Is This Development So Important?
For decades, scientists knew that abnormal RAS signaling played an enormous role in pancreatic cancer.
Knowing what drives a cancer and being able to successfully target it, however, are two very different things.
RAS was once considered essentially “undruggable.”
The daraxonrasib results provide evidence that directly targeting active RAS signaling can produce meaningful clinical benefits in pancreatic cancer.
The Phase III trial did not simply demonstrate changes on laboratory tests or imaging.
It demonstrated improvements in two outcomes that matter enormously to patients:
How long people lived and how long their cancer remained controlled.
That is why these results have received so much attention within the oncology community.
Is Daraxonrasib Being Studied Earlier in Pancreatic Cancer?
Yes.
Researchers are now investigating whether daraxonrasib could potentially help patients at other stages of pancreatic cancer.
For example, another Phase III study called RASolute 304 is evaluating daraxonrasib in people whose pancreatic cancer has been surgically removed and who have completed chemotherapy.
That trial is studying whether daraxonrasib can help delay or prevent the cancer from returning compared with observation alone.
This is an important question because a medication that works in advanced disease may sometimes provide even greater benefit when used earlier in the course of cancer.
However, those results are not yet available.
What Does This Mean for Someone With Pancreatic Cancer Today?
The results are encouraging, but they should not change treatment without consultation with an oncology team.
Someone with pancreatic cancer should discuss several questions with their oncologist:
- What type and stage of pancreatic cancer do I have?
- Has my tumor undergone molecular or genetic testing?
- What treatments are currently recommended for me?
- Are clinical trials appropriate?
- Could I qualify for an expanded-access program?
- Should I be evaluated at a pancreatic cancer specialty center?
Treatment decisions depend on much more than a single study, including previous treatments, cancer stage, molecular findings, overall health and individual treatment goals.
What Should You Do Next?
Daraxonrasib represents one of the more encouraging recent developments in pancreatic cancer treatment.
In a 500-patient Phase III trial, people with previously treated metastatic pancreatic ductal adenocarcinoma who received daraxonrasib had a median overall survival of 13.2 months compared with 6.7 months with chemotherapy.
That is a meaningful result in a cancer that has historically been extremely difficult to treat.
But daraxonrasib is not a cure, and it is not yet FDA approved.
The next major step will be the FDA’s evaluation of whether the evidence is sufficient for approval. Researchers are also studying whether targeting RAS with daraxonrasib could benefit patients at earlier stages of pancreatic cancer.
For patients and families affected by pancreatic cancer, the findings offer something that has been difficult to achieve in this disease: evidence that directly targeting one of pancreatic cancer’s most important biological drivers can meaningfully extend survival.